WO2024007532A1 - Method for determining dissolution rates of eight representative components in daochi pills - Google Patents

Method for determining dissolution rates of eight representative components in daochi pills Download PDF

Info

Publication number
WO2024007532A1
WO2024007532A1 PCT/CN2022/138253 CN2022138253W WO2024007532A1 WO 2024007532 A1 WO2024007532 A1 WO 2024007532A1 CN 2022138253 W CN2022138253 W CN 2022138253W WO 2024007532 A1 WO2024007532 A1 WO 2024007532A1
Authority
WO
WIPO (PCT)
Prior art keywords
dissolution
pills
daochi
solution
baicalin
Prior art date
Application number
PCT/CN2022/138253
Other languages
French (fr)
Chinese (zh)
Inventor
曹春琪
刘永利
周亚楠
孔亚萍
苏建
Original Assignee
河北省药品医疗器械检验研究院(河北省化妆品检验研究中心)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) filed Critical 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心)
Publication of WO2024007532A1 publication Critical patent/WO2024007532A1/en

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/86Signal analysis
    • G01N30/8675Evaluation, i.e. decoding of the signal into analytical information
    • G01N30/8679Target compound analysis, i.e. whereby a limited number of peaks is analysed
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N2030/042Standards
    • G01N2030/047Standards external
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • G01N2030/065Preparation using different phases to separate parts of sample

Definitions

  • the invention belongs to the field of drug analysis and detection, and is specifically a method for measuring the dissolution of eight representative components in Daochi Pills.
  • Daochi Pills are composed of ten medicinal herbs, including Forsythia suspensa, Coptis chinensis, Gardenia jasminoides (fried with ginger), Akebia bark, Scrophulariaceae, Trichosanthes trichosanthes, red peony root, rhubarb, skullcap, and talc.
  • Volume 6 of "Minheji Bureau Prescriptions” is now included in the 2020 edition of "Chinese Pharmacopoeia”. It is commonly used clinically for sores on the mouth and tongue, sore throat, irritability in the chest and chest, short red urine, and constipation caused by internal heat accumulation.
  • Traditional Chinese medicine preparations are mostly produced using traditional techniques.
  • the dissolution rate of a drug refers to the speed and degree of drug dissolution in a specified solvent.
  • the dissolution rate has a direct impact on the absorption and utilization of the drug in the body.
  • Drug dissolution testing is an effective means to evaluate the quality and process level of preparations. It can reflect differences in prescription composition, excipients, and production processes to a certain extent. Therefore, it is necessary to conduct dissolution testing on Daochi Pills.
  • the UPLC-MS/MS method is used to determine 8 representative ingredients in Daochi Pills: baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid B, harpagoside, gardeniposide, paeoniflorin, and forsythiarin.
  • the dissolution rate of glycoside A has not been reported.
  • the purpose of the present invention is to address the above problems and provide a method for measuring the dissolution of 8 representative ingredients in Daochi Pills, which includes the following steps:
  • Chromatographic conditions Chromatographic column: phenomenon C18 column 2.6 ⁇ m, 2.1 ⁇ 100mm; acetonitrile as mobile phase A, 0.1% formic acid as mobile phase B, gradient elution; column temperature: 40°C, flow rate: 0.3ml/min; injection Volume: 1 ⁇ l;
  • Mass spectrometry conditions electrospray ion source ESI, scanning mode: simultaneous scanning of positive and negative ions, monitoring mode: multiple reaction monitoring mode MRM, positive ionization voltage: 5500V, desolvation gas temperature: 500°C, negative ionization voltage: -4500V, desolvation Air temperature: 500°C.
  • the mixed reference solution is prepared by the following steps: accurately weighing baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid B, harpagoside, gardeniposide, paeoniflorin, Forsythiaside
  • a reference substance is an appropriate amount, and methanol is added to prepare it.
  • Each 1ml contains about 70 ⁇ g of baicalin, 22 ⁇ g of berberine hydrochloride, 1 ⁇ g of aloe emodin, 1 ⁇ g of Akebia phenylethanoid glycoside B, 2 ⁇ g of harpagoside, and 60 ⁇ g of gardeniposide.
  • a mixed solution of 14 ⁇ g of paeoniflorin and 70 ⁇ g of forsythiaside A is obtained.
  • the gradient elution procedure is as follows:
  • the present invention has established a method for testing the dissolution of Daochi Pills and Water Honey Pills using the UPLC-MS/MS method.
  • the active ingredient baicalin of Scutellaria baicalensis, Coptis chinensis, rhubarb, Akebia, Scrophulariaceae, Gardenia, red peony root and Forsythia suspensa in the prescription is , berberine hydrochloride, aloe-emodin, phytoside B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A dissolution were measured and analyzed, thereby conducting a comprehensive evaluation of the drug quality of Daochi Pills.
  • the evaluation can provide reference for its quality control and drug efficacy verification.
  • Figures 1 to 24 respectively show baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid glycoside B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside in different dissolution cups of the same batch of Daochi pills.
  • the dissolution curve of A (with time as the abscissa and dissolution as the ordinate);
  • Figures 25 to 32 respectively show the average values of baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A in different batches of Daochi Pills.
  • Dissolution curve graph (with time as the abscissa and average dissolution as the ordinate).
  • the purpose of the present invention is to provide a method for measuring the dissolution of eight representative components of Daochi Pills.
  • the present invention uses the UPLC-MS/MS method to determine baicalin, berberine hydrochloride, aloe-emodin, and Akebia phenylethanoid glycoside B. , dissolution of harpagoside, gardeniposide, paeoniflorin, and forsythiaside A.
  • Chromatographic conditions Chromatographic column: phenomenon C18 column (2.6 ⁇ m, 2.1 ⁇ 100mm); use acetonitrile as mobile phase A and 0.1% formic acid as mobile phase B.
  • the gradient elution procedure is shown in Table 1; column temperature: 40°C, flow rate: 0.3 ml/min; injection volume: 1 ⁇ l.
  • Preparation of the mixed reference solution Precisely weigh appropriate amounts of baicalin, berberine hydrochloride, aloe-emodin, aphylloside B, hapagoside, gardeniposide, paeoniflorin, and forsythiaside A reference substances. Add methanol to make each 1ml containing about 70 ⁇ g of baicalin, 22 ⁇ g of berberine hydrochloride, 1 ⁇ g of aloe-emodin, 1 ⁇ g of Akebia phenylethanoid glycoside B, 2 ⁇ g of hapagoside, 60 ⁇ g of gardeniposide, 14 ⁇ g of paeoniflorin, and forsythiaside. A 70 ⁇ g mixed solution is obtained.
  • Aloe emodin (CCI, batch number: 110795-201308, content 97.8%)
  • Reagents methanol, acetonitrile, and formic acid are all chromatographically pure, and water is ultrapure water. 10 batches of samples of Daochi Pills and Water Honey Pills.
  • acetonitrile as mobile phase A and 0.1% formic acid as mobile phase B.
  • the gradient elution program is shown in Table 1. The flow rate is 0.3mL ⁇ min-1, the column temperature is 40°C, and the injection volume is 1 ⁇ L.
  • the method of the present invention can treat the active ingredients of baicalin, berberine hydrochloride, aloe-emodin, baicalin, berberine hydrochloride, and aloe-emodin in the prescription of Daochi Pills.
  • the dissolution rates of Akebia acutaphylla glycoside B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A were measured and analyzed, thereby comprehensively evaluating the quality of Daochi Pills, which can be used for quality control and pharmaceutical preparation. Provide reference for validation.

Landscapes

  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Library & Information Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to the field of drug analysis and detection, and provides a method for determining dissolution rates of eight representative components in Daochi pills, which comprises the following steps: preparing a mixed reference solution: taking 200 mL of degassed hydrochloric acid solution having a pH value of 1.0 as a dissolution medium, keeping the temperature at 37±0.5°C and the rotating speed at 80 r/min, lowering the solution into a container by means of a paddle, performing sampling after 180 min to obtain 2 mL of a product, and filtering same by using a 0.22 μm microporous filter membrane, so as to obtain the mixed reference solution; preparing a test solution; and precisely suctioning 1 μl of the mixed reference solution and 1 μl of the test solution, respectively, injecting same into an ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) instrument, performing determination, and calculating content by means of an external standard method. According to the present invention, the dissolution rates of baicalin, berberine hydrochloride, aloe-emodin, calceolarioside B, harpagoside, geniposide, paeoniflorin, and forsythiaside A are determined by using a UPLC-MS/MS method, so that the medicine quality of Daochi pills is comprehensively evaluated, and a reference can be provided for quality control and efficacy verification of Daochi pills.

Description

一种导赤丸中8种代表性成分的溶出度测定方法A method for determining the dissolution of 8 representative ingredients in Daochi Pills 技术领域Technical field
本发明属于药物分析检测领域,具体是一种导赤丸中8种代表性成分的溶出度测定方法。The invention belongs to the field of drug analysis and detection, and is specifically a method for measuring the dissolution of eight representative components in Daochi Pills.
背景技术Background technique
导赤丸由连翘、黄连、栀子(姜炒)、木通、玄参、天花粉、赤芍、大黄、黄芩、滑石共十味药组成,出自宋代太平惠民和剂局编写的《太平惠民和剂局方》卷六,现收载于《中国药典》2020年版,临床常用于火热内盛所致的口舌生疮、咽喉疼痛、心胸烦热、小便短赤、大便秘结。中药制剂生产多为传统工艺,各厂家原辅料、生产条件以及工艺的不同,均可造成产品质量参差不齐,从而影响成药的临床疗效。药物的溶出度是指药物在规定溶剂中溶出的速度和程度,溶出度对药物在体内的吸收利用产生直接影响。药物的溶出度检查是评价制剂质量和工艺水平的一种有效手段,可在一定程度上反映处方组成,辅料、生产工艺的差异,故有必要对导赤丸进行溶出度检查。目前采用UPLC-MS/MS法测定导赤丸中8种代表性成分黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A的溶出度尚未见报道。Daochi Pills are composed of ten medicinal herbs, including Forsythia suspensa, Coptis chinensis, Gardenia jasminoides (fried with ginger), Akebia bark, Scrophulariaceae, Trichosanthes trichosanthes, red peony root, rhubarb, skullcap, and talc. Volume 6 of "Minheji Bureau Prescriptions" is now included in the 2020 edition of "Chinese Pharmacopoeia". It is commonly used clinically for sores on the mouth and tongue, sore throat, irritability in the chest and chest, short red urine, and constipation caused by internal heat accumulation. Traditional Chinese medicine preparations are mostly produced using traditional techniques. Differences in raw materials, excipients, production conditions and processes among various manufacturers can cause uneven product quality, thus affecting the clinical efficacy of finished medicines. The dissolution rate of a drug refers to the speed and degree of drug dissolution in a specified solvent. The dissolution rate has a direct impact on the absorption and utilization of the drug in the body. Drug dissolution testing is an effective means to evaluate the quality and process level of preparations. It can reflect differences in prescription composition, excipients, and production processes to a certain extent. Therefore, it is necessary to conduct dissolution testing on Daochi Pills. Currently, the UPLC-MS/MS method is used to determine 8 representative ingredients in Daochi Pills: baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid B, harpagoside, gardeniposide, paeoniflorin, and forsythiarin. The dissolution rate of glycoside A has not been reported.
发明内容Contents of the invention
本发明的目的是针对以上问题,提供了一种导赤丸中8种代表性成分的溶出度测定方法,包括以下步骤:The purpose of the present invention is to address the above problems and provide a method for measuring the dissolution of 8 representative ingredients in Daochi Pills, which includes the following steps:
A.制备混合对照品溶液;A. Prepare mixed reference solution;
B.制备供试品溶液:取导赤丸水蜜丸6丸,以200mL经脱气处理的pH=1.0盐酸溶液为溶出介质,温度保持在37±0.5℃,转速80r/min,桨降入容器中,立即开始计时,分别于5、15、40、80、120、150、180min时取样2mL,同 时补加同温等量的溶出介质,用0.22μm微孔滤膜滤过,即得;B. Prepare the test solution: Take 6 pills of Daochiwan Shuimiwan, use 200mL of degassed pH=1.0 hydrochloric acid solution as the dissolution medium, keep the temperature at 37±0.5℃, rotate at 80r/min, and lower the paddle into the container. , start timing immediately, take a sample of 2 mL at 5, 15, 40, 80, 120, 150, and 180 minutes respectively, add the same amount of dissolution medium at the same temperature, and filter with a 0.22 μm microporous membrane to obtain;
C.分别精密吸取混合对照品溶液与供试品溶液各1μl,注入超高效液相色谱质谱联用仪,测定,外标法计算含量,即得;C. Precisely draw 1 μl each of the mixed reference solution and the test solution, inject into the ultra-high performance liquid chromatography mass spectrometer, measure, and calculate the content with the external standard method, and you get;
色谱条件:色谱柱:phenomenon C18柱2.6μm,2.1×100mm;以乙腈为流动相A,0.1%甲酸为流动相B,梯度洗脱;柱温:40℃,流速:0.3ml/min;进样量:1μl;Chromatographic conditions: Chromatographic column: phenomenon C18 column 2.6μm, 2.1×100mm; acetonitrile as mobile phase A, 0.1% formic acid as mobile phase B, gradient elution; column temperature: 40°C, flow rate: 0.3ml/min; injection Volume: 1μl;
质谱条件:电喷雾离子源ESI,扫描方式:正负离子同时扫描,监测模式:多反应监测模式MRM,正离子化电压:5500V,脱溶剂气温度:500℃,负离子化电压:-4500V,脱溶剂气温度:500℃。Mass spectrometry conditions: electrospray ion source ESI, scanning mode: simultaneous scanning of positive and negative ions, monitoring mode: multiple reaction monitoring mode MRM, positive ionization voltage: 5500V, desolvation gas temperature: 500°C, negative ionization voltage: -4500V, desolvation Air temperature: 500℃.
优选的,所述混合对照品溶液由如下步骤配置而成:分别精密称取黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A对照品适量,加甲醇分别制成每1ml含黄芩苷约70μg、盐酸小檗碱22μg、芦荟大黄素1μg、木通苯乙醇苷B 1μg、哈巴俄苷2μg、栀子苷60μg、芍药苷14μg、连翘酯苷A 70μg的混合溶液,即得。Preferably, the mixed reference solution is prepared by the following steps: accurately weighing baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid B, harpagoside, gardeniposide, paeoniflorin, Forsythiaside A reference substance is an appropriate amount, and methanol is added to prepare it. Each 1ml contains about 70 μg of baicalin, 22 μg of berberine hydrochloride, 1 μg of aloe emodin, 1 μg of Akebia phenylethanoid glycoside B, 2 μg of harpagoside, and 60 μg of gardeniposide. A mixed solution of 14 μg of paeoniflorin and 70 μg of forsythiaside A is obtained.
优选的,所述步骤B中的pH=1.0盐酸溶液的制备:精密量取盐酸9.00mL,用水稀释至1000mL,摇匀,即得。Preferably, the pH=1.0 hydrochloric acid solution in step B is prepared by precisely measuring 9.00 mL of hydrochloric acid, diluting it with water to 1000 mL, and shaking evenly.
优选的,梯度洗脱程序如下:Preferably, the gradient elution procedure is as follows:
流动相梯度洗脱程序Mobile phase gradient elution procedure
Figure PCTCN2022138253-appb-000001
Figure PCTCN2022138253-appb-000001
与现有技术相比,本发明的有益效果如下:Compared with the prior art, the beneficial effects of the present invention are as follows:
本发明建立了采用UPLC-MS/MS法测定导赤丸水蜜丸的溶出度检查方法,对处方中黄芩、黄连、大黄、木通、玄参、栀子、赤芍、连翘的有效成分黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A的溶出度进行测定分析,从而对导赤丸药品质量进行了全方位的评估,可为其质量控制以及药效验证提供参考。The present invention has established a method for testing the dissolution of Daochi Pills and Water Honey Pills using the UPLC-MS/MS method. The active ingredient baicalin of Scutellaria baicalensis, Coptis chinensis, rhubarb, Akebia, Scrophulariaceae, Gardenia, red peony root and Forsythia suspensa in the prescription is , berberine hydrochloride, aloe-emodin, phytoside B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A dissolution were measured and analyzed, thereby conducting a comprehensive evaluation of the drug quality of Daochi Pills. The evaluation can provide reference for its quality control and drug efficacy verification.
附图说明Description of the drawings
图1-图24分别为同一批次导赤丸不同溶出杯中黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A的溶出曲线图(以时间为横坐标,溶出度为纵坐标);Figures 1 to 24 respectively show baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid glycoside B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside in different dissolution cups of the same batch of Daochi pills. The dissolution curve of A (with time as the abscissa and dissolution as the ordinate);
图25-图32分别为不同批次导赤丸中黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A的平均溶出曲线图(以时间为横坐标,平均溶出度为纵坐标)。Figures 25 to 32 respectively show the average values of baicalin, berberine hydrochloride, aloe-emodin, Akebia phenylethanoid B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A in different batches of Daochi Pills. Dissolution curve graph (with time as the abscissa and average dissolution as the ordinate).
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts fall within the scope of protection of the present invention.
本发明的目的在于提供了一种导赤丸8种代表性成分的溶出度测定方法,本发明采用UPLC-MS/MS法测定黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A的溶出度。本发明含量测定方法采用桨法进行溶出,以PH=1.0的盐酸溶液为溶出介质,转速为80r/min,取样时间为5、15、40、80、120、150、180min。色谱条件:色谱柱:phenomenon C18柱(2.6μm,2.1×100mm);以乙腈为流动相A,0.1%甲酸为流动相B,梯度洗脱程序见表1;柱温:40℃,流速:0.3ml/min;进样量:1μl。The purpose of the present invention is to provide a method for measuring the dissolution of eight representative components of Daochi Pills. The present invention uses the UPLC-MS/MS method to determine baicalin, berberine hydrochloride, aloe-emodin, and Akebia phenylethanoid glycoside B. , dissolution of harpagoside, gardeniposide, paeoniflorin, and forsythiaside A. The content determination method of the present invention adopts the paddle method for dissolution, using hydrochloric acid solution with pH=1.0 as the dissolution medium, the rotation speed is 80r/min, and the sampling time is 5, 15, 40, 80, 120, 150, and 180min. Chromatographic conditions: Chromatographic column: phenomenon C18 column (2.6μm, 2.1×100mm); use acetonitrile as mobile phase A and 0.1% formic acid as mobile phase B. The gradient elution procedure is shown in Table 1; column temperature: 40°C, flow rate: 0.3 ml/min; injection volume: 1μl.
表1流动相梯度洗脱程序Table 1 Mobile phase gradient elution procedure
Figure PCTCN2022138253-appb-000002
Figure PCTCN2022138253-appb-000002
以三重四极杆串联质谱仪检测;电喷雾离子源(ESI),扫描方式:正负离子同时扫描,监测模式:多反应监测模式(MRM),正离子化电压:5500V,脱溶剂气温度:500℃,负离子化电压:-4500V,脱溶剂气温度:500℃;质谱参数详见表2。Detected by triple quadrupole tandem mass spectrometer; electrospray ion source (ESI), scanning mode: simultaneous scanning of positive and negative ions, monitoring mode: multiple reaction monitoring mode (MRM), positive ionization voltage: 5500V, desolvation gas temperature: 500 ℃, negative ionization voltage: -4500V, desolvation gas temperature: 500℃; mass spectrometry parameters are detailed in Table 2.
表2定性和定量离子及质谱条件表Table 2 Qualitative and quantitative ions and mass spectrometry conditions
Figure PCTCN2022138253-appb-000003
Figure PCTCN2022138253-appb-000003
混合对照品溶液的制备:分别精密称取黄芩苷、盐酸小檗碱、芦荟大黄 素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A对照品适量,加甲醇分别制成每1ml含黄芩苷约70μg、盐酸小檗碱22μg、芦荟大黄素1μg、木通苯乙醇苷B 1μg、哈巴俄苷2μg、栀子苷60μg、芍药苷14μg、连翘酯苷A 70μg的混合溶液,即得。Preparation of the mixed reference solution: Precisely weigh appropriate amounts of baicalin, berberine hydrochloride, aloe-emodin, aphylloside B, hapagoside, gardeniposide, paeoniflorin, and forsythiaside A reference substances. Add methanol to make each 1ml containing about 70μg of baicalin, 22μg of berberine hydrochloride, 1μg of aloe-emodin, 1μg of Akebia phenylethanoid glycoside B, 2μg of hapagoside, 60μg of gardeniposide, 14μg of paeoniflorin, and forsythiaside. A 70μg mixed solution is obtained.
溶出介质的制备:按《普通口服固体制剂溶出度试验技术指导原则》中溶出介质的方法配制溶出介质溶液,pH=1.0盐酸溶液:精密量取盐酸9.00mL,用水稀释至1000mL,摇匀,即得。Preparation of dissolution medium: Prepare the dissolution medium solution according to the method of dissolution medium in "Technical Guidelines for Dissolution Test of General Oral Solid Preparations", pH=1.0 hydrochloric acid solution: Precisely measure 9.00mL of hydrochloric acid, dilute it with water to 1000mL, shake well, that is have to.
1.仪器与试药1.Instruments and reagents
1.1仪器1.1 Instruments
AB SCIEX Qtrap 6500超高效液相色谱-离子阱质谱联用仪;分析天平:Mettler XPE26(百万分之一);Mettler XS105(十万分之一)(上海梅特勒仪器有限公司);KQ-400KDE超声波清洗仪(昆山市超声仪器有限公司);AB SCIEX Qtrap 6500 ultra-high performance liquid chromatography-ion trap mass spectrometer; analytical balance: Mettler XPE26 (one part per million); Mettler XS105 (one hundred thousandth) (Shanghai Mettler Instrument Co., Ltd.); KQ -400KDE ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.);
1.2试药1.2 Test medicine
黄芩苷(中检院,批号:110715-201117,含量91.7%)Baicalin (CCI, batch number: 110715-201117, content 91.7%)
盐酸小檗碱(中检院,批号:110713-201814,含量86.7%)Berberine hydrochloride (CCI, batch number: 110713-201814, content 86.7%)
芦荟大黄素(中检院,批号:110795-201308,含量97.8%)Aloe emodin (CCI, batch number: 110795-201308, content 97.8%)
木通苯乙醇苷B(中检院,批号:111910-201604,含量98.2%)Akebia phenylethanol glycoside B (CCI, batch number: 111910-201604, content 98.2%)
哈巴俄苷(中检院,批号:111730-201709,含量95.9%)Harpagoside (CCI, batch number: 111730-201709, content 95.9%)
芍药苷(中检院,批号:110736-201942,含量95.1%)Paeoniflorin (CCI, batch number: 110736-201942, content 95.1%)
连翘酯苷A(中检院,批号:111810-201606,含量93.4%)Forsythiaside A (CCI, batch number: 111810-201606, content 93.4%)
栀子苷(中检院,批号:110749-201919,含量97.1%)Geniposide (CCI, batch number: 110749-201919, content 97.1%)
试剂:甲醇、乙腈、甲酸均为色谱纯,水为超纯水。导赤丸水蜜丸样品10批。Reagents: methanol, acetonitrile, and formic acid are all chromatographically pure, and water is ultrapure water. 10 batches of samples of Daochi Pills and Water Honey Pills.
2.方法与结果2. Methods and results
2.1色谱条件2.1 Chromatographic conditions
以乙腈为流动相A,0.1%甲酸为流动相B,梯度洗脱程序见表1,流速0.3mL·min-1,柱温40℃,进样量为1μL。Use acetonitrile as mobile phase A and 0.1% formic acid as mobile phase B. The gradient elution program is shown in Table 1. The flow rate is 0.3mL·min-1, the column temperature is 40°C, and the injection volume is 1 μL.
表1流动相梯度洗脱程序Table 1 Mobile phase gradient elution procedure
Figure PCTCN2022138253-appb-000004
Figure PCTCN2022138253-appb-000004
2.2对照品溶液的制备分别精密称取黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A对照品适量,加甲醇分别制成每1ml含黄芩苷约70μg、盐酸小檗碱22μg、芦荟大黄素1μg、木通苯乙醇苷B 1μg、哈巴俄苷2μg、栀子苷60μg、芍药苷14μg、连翘酯苷A70μg的混合溶液,即得。2.2 Preparation of reference solution: Accurately weigh appropriate amounts of baicalin, berberine hydrochloride, aloe-emodin, aphylloside B, hapagoside, gardeniposide, paeoniflorin, and forsythiaside A reference substances, and add Each 1ml made of methanol contains about 70 μg of baicalin, 22 μg of berberine hydrochloride, 1 μg of aloe-emodin, 1 μg of Ayatoside phenylethanoid glycoside B, 2 μg of hapagoside, 60 μg of gardeniposide, 14 μg of paeoniflorin, and 70 μg of forsythiaside A. The mixed solution is obtained.
2.3溶出介质的制备:按《普通口服固体制剂溶出度试验技术指导原则》中溶出介质的方法配制溶出介质溶液,pH=1.0盐酸溶液:精密量取盐酸9.00mL,用水稀释至1000mL,摇匀,即得。2.3 Preparation of dissolution medium: Prepare the dissolution medium solution according to the method of dissolution medium in "Technical Guidelines for Dissolution Test of General Oral Solid Preparations", pH=1.0 hydrochloric acid solution: Precisely measure 9.00mL of hydrochloric acid, dilute to 1000mL with water, shake well, That’s it.
2.4溶出条件筛选2.4 Screening of dissolution conditions
2.4.1溶出介质的考察:以厂家A生产的导赤丸(批号:20201001)为研究对象,分别取6丸置于200mL“2.3”项下的介质和200mL水溶出介质中,按2020年版《中国药典》(四部)通则“溶出度与释放度测定法”项下桨法进行操作,分别置上述2种溶出介质中,结果显示,在2种介质中导赤丸中的黄芩苷、盐酸小檗碱、芦荟大黄素、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A在pH=1.0盐酸溶液中溶出最好,在水中溶出较差,综合考虑,该样品的溶出介质为pH=1.0盐酸溶液时较佳。2.4.1 Investigation of the dissolution medium: Taking Daochi pills (batch number: 20201001) produced by manufacturer A as the research object, take 6 pills and place them in 200mL of the medium under "2.3" and 200mL of water dissolution medium. According to the 2020 version of "China The paddle method was operated under the general chapter "Dissolution and Release Measurement Methods" of the Pharmacopoeia (Part IV), and the above two dissolution media were placed respectively. The results showed that in the two media, baicalin and berberine hydrochloride in Daochi Pills , aloe-emodin, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A are best dissolved in hydrochloric acid solution at pH=1.0, but poorly dissolved in water. Considering all things considered, the dissolution medium of this sample is pH=1.0 Hydrochloric acid solution is preferred.
2.4.2转速的选择:通过预试验发现转速对本品的溶出影响较大,分别考察了转速为40、80和120r/min的溶出情况,结果表明80r/min时导赤丸的溶出较好,更具有区分力,因此选择80r/min来进行导赤丸的溶出度研究。2.4.2 Selection of rotation speed: Through preliminary tests, it was found that the rotation speed has a greater impact on the dissolution of this product. The dissolution conditions of the rotation speeds of 40, 80 and 120 r/min were investigated respectively. The results showed that the dissolution of Daochi Pills was better at 80 r/min. It has more discriminating power, so 80r/min was chosen to conduct the dissolution study of Daochi Pills.
2.4.3取样时间的考察:以20201001批号导赤丸为研究对象,分别考察了5、15、40、80、120、150、180、240min的溶出度。结果表明,在180min内黄芩苷等成分溶出已达到平衡,所以确定取样溶出时间为180min。2.4.3 Investigation of sampling time: Taking the 20201001 batch number Daochi Pills as the research object, the dissolution rates of 5, 15, 40, 80, 120, 150, 180, and 240 minutes were investigated respectively. The results showed that the dissolution of components such as baicalin had reached equilibrium within 180 minutes, so the sampling dissolution time was determined to be 180 minutes.
2.5样品批内均一性评价2.5 Evaluation of intra-batch homogeneity of samples
按《中国药典》2020年版四部通则“溶出度与释放度测定法”项下第二法桨法测定,选取3个不同批号,1次试验6丸,以200mL经脱气处理的pH=1.0盐酸溶液为溶出介质,温度保持在(37±0.5)℃,转速80r/min。桨降入容器中,立即开始计时,分别于5、15、40、80、120、150、180min时取样2mL(同时补加同温等量的溶出介质),用0.22μm微孔滤膜滤过,取续滤液1μL,进样,测定黄芩苷、盐酸小檗碱等成分的含量,以不同溶出杯中黄芩苷、盐酸小檗碱等溶出量除以溶出样品中每成分最大溶出量计算不同溶出杯中黄芩苷、盐酸小檗碱等的溶出度,并以时间为横坐标,溶出度为纵坐标绘制溶出曲线。结果见图1-图24。结果表明不同批次批内均一性良好,重复性良好,测定方法准确度高。According to the second paddle method under the "Dissolution and Release Measurement Method" of the Four General Chapters of the 2020 Edition of the "Chinese Pharmacopoeia", 3 different batch numbers were selected, 6 pills were tested at one time, and 200 mL of degassed pH=1.0 hydrochloric acid was used. The solution is the dissolution medium, the temperature is maintained at (37±0.5)℃, and the rotation speed is 80r/min. Lower the paddle into the container and start timing immediately. Take 2 mL samples at 5, 15, 40, 80, 120, 150, and 180 minutes (while adding an equal amount of dissolution medium at the same temperature), and filter with a 0.22 μm microporous membrane. , take 1 μL of the continued filtrate, inject a sample, and determine the content of baicalin, berberine hydrochloride and other components. Divide the dissolution volume of baicalin, berberine hydrochloride, etc. in different dissolution cups by the maximum dissolution volume of each component in the dissolution sample to calculate different dissolutions The dissolution rate of baicalin, berberine hydrochloride, etc. in the cup, and the dissolution curve is drawn with time as the abscissa and dissolution rate as the ordinate. The results are shown in Figure 1-Figure 24. The results showed that different batches had good intra-batch homogeneity and good repeatability, and the determination method had high accuracy.
2.6样品不同批次溶出曲线测定2.6 Determination of dissolution curves of different batches of samples
取5批不同批次导赤丸,每个批次6丸,按《中国药典》2015年版四部通则“溶出度与释放度测定法”项下第二法浆法测定,以200mL经脱气处理的水溶液为溶出介质,温度保持在(37±0.5)℃,转速80r/min。桨降入容器中,立即开始计时,分别于5、15、40、80、120、150、180min时取样2mL(同时补加同温等量的溶出介质),用0.22μm微孔滤膜滤过,取续滤液1μL,进样,测定栀子苷、黄芩苷等的含量,以不同时间栀子苷、黄芩苷等平均溶出量除以溶出样品中栀子苷、黄芩苷等最大溶出量计算不同时刻导赤丸中栀子苷、黄芩苷等的平均溶出度,并以时间为横坐标,平均溶出度为纵坐标绘制溶出曲线。结果见图25-图32。Take 5 different batches of Daochi pills, 6 pills in each batch, and measure according to the second method of the slurry method under the "Dissolution and Release Determination Method" of the Four General Chapters of the 2015 edition of the "Chinese Pharmacopoeia", using 200 mL of degassed The aqueous solution is the dissolution medium, the temperature is maintained at (37±0.5)℃, and the rotation speed is 80r/min. Lower the paddle into the container and start timing immediately. Take 2 mL samples at 5, 15, 40, 80, 120, 150, and 180 minutes (while adding an equal amount of dissolution medium at the same temperature), and filter with a 0.22 μm microporous membrane. , take 1 μL of the continued filtrate, inject a sample, and determine the content of gardeniposide, baicalin, etc., and calculate the difference by dividing the average dissolution amount of gardeniposide, baicalin, etc. at different times by the maximum dissolution amount of gardeniposide, baicalin, etc. in the dissolution sample The average dissolution of gardeniposide, baicalin, etc. in Shidaochi Pills was calculated, and the dissolution curve was drawn with time as the abscissa and the average dissolution as the ordinate. The results are shown in Figure 25-Figure 32.
综上所述,本发明的方法可对导赤丸处方中黄芩、黄连、大黄、木通、玄参、栀子、赤芍、连翘的有效成分黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A的溶出度进行测定分析,从而对导赤丸药品质量进行了全方位的评估,可为其质量控制以及药 效验证提供参考。In summary, the method of the present invention can treat the active ingredients of baicalin, berberine hydrochloride, aloe-emodin, baicalin, berberine hydrochloride, and aloe-emodin in the prescription of Daochi Pills. The dissolution rates of Akebia acutaphylla glycoside B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A were measured and analyzed, thereby comprehensively evaluating the quality of Daochi Pills, which can be used for quality control and pharmaceutical preparation. Provide reference for validation.
需要说明的是,在本申请中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。It should be noted that in this application, relational terms such as first and second are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that these entities or operations There is no such actual relationship or sequence between them. Furthermore, the terms "comprises," "comprises," or any other variations thereof are intended to cover a non-exclusive inclusion such that a process, method, article, or apparatus that includes a list of elements includes not only those elements, but also those not expressly listed other elements, or elements inherent to the process, method, article or equipment.
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。Although the embodiments of the present invention have been shown and described, those of ordinary skill in the art will understand that various changes, modifications, and substitutions can be made to these embodiments without departing from the principles and spirit of the invention. and modifications, the scope of the invention is defined by the appended claims and their equivalents.

Claims (4)

  1. 一种导赤丸中8种代表性成分的溶出度测定方法,其特征在于,包括以下步骤:A method for measuring the dissolution of 8 representative ingredients in Daochi Pills, which is characterized by including the following steps:
    A.制备混合对照品溶液;A. Prepare mixed reference solution;
    B.制备供试品溶液:取导赤丸水蜜丸6丸,以200mL经脱气处理的pH=1.0盐酸溶液为溶出介质,温度保持在37±0.5℃,转速80r/min,桨降入容器中,立即开始计时,分别于5、15、40、80、120、150、180min时取样2mL,同时补加同温等量的溶出介质,用0.22μm微孔滤膜滤过,即得;B. Prepare the test solution: Take 6 pills of Daochiwan Shuimiwan, use 200mL of degassed pH=1.0 hydrochloric acid solution as the dissolution medium, keep the temperature at 37±0.5℃, rotate at 80r/min, and lower the paddle into the container. , start timing immediately, take a sample of 2 mL at 5, 15, 40, 80, 120, 150, and 180 minutes respectively, add the same amount of dissolution medium at the same temperature, and filter with a 0.22 μm microporous filter membrane to obtain;
    C.分别精密吸取混合对照品溶液与供试品溶液各1μl,注入超高效液相色谱质谱联用仪,测定,外标法计算含量,即得;C. Precisely draw 1 μl each of the mixed reference solution and the test solution, inject into the ultra-high performance liquid chromatography mass spectrometer, measure, and calculate the content with the external standard method, and you get;
    色谱条件:色谱柱:phenomenon C18柱2.6μm,2.1×100mm;以乙腈为流动相A,0.1%甲酸为流动相B,梯度洗脱;柱温:40℃,流速:0.3ml/min;进样量:1μl;Chromatographic conditions: Chromatographic column: phenomenon C18 column 2.6μm, 2.1×100mm; acetonitrile as mobile phase A, 0.1% formic acid as mobile phase B, gradient elution; column temperature: 40°C, flow rate: 0.3ml/min; injection Volume: 1μl;
    质谱条件:电喷雾离子源ESI,扫描方式:正负离子同时扫描,监测模式:多反应监测模式MRM,正离子化电压:5500V,脱溶剂气温度:500℃,负离子化电压:-4500V,脱溶剂气温度:500℃。Mass spectrometry conditions: electrospray ion source ESI, scanning mode: simultaneous scanning of positive and negative ions, monitoring mode: multiple reaction monitoring mode MRM, positive ionization voltage: 5500V, desolvation gas temperature: 500°C, negative ionization voltage: -4500V, desolvation Air temperature: 500℃.
  2. 根据权利要求1所述的一种导赤丸中8种代表性成分的溶出度测定方法,其特征在于,所述混合对照品溶液由如下步骤配置而成:分别称取黄芩苷、盐酸小檗碱、芦荟大黄素、木通苯乙醇苷B、哈巴俄苷、栀子苷、芍药苷、连翘酯苷A对照品,加甲醇分别制成每1ml含黄芩苷70μg、盐酸小檗碱22μg、芦荟大黄素1μg、木通苯乙醇苷B1μg、哈巴俄苷2μg、栀子苷60μg、芍药苷14μg、连翘酯苷A70μg的混合溶液,即得。A method for measuring the dissolution of 8 representative components in Daochi pills according to claim 1, characterized in that the mixed reference solution is configured by the following steps: weigh baicalin and berberine hydrochloride respectively , aloe-emodin, phytoside B, harpagoside, gardeniposide, paeoniflorin, and forsythiaside A reference substances were prepared by adding methanol and containing 70 μg of baicalin, 22 μg of berberine hydrochloride, and aloe vera per 1 ml. A mixed solution of 1 μg of emodin, 1 μg of Ayatoside B, 2 μg of Harpagoside, 60 μg of Geniposide, 14 μg of Paeoniflorin, and 70 μg of Forsythiaside A is obtained.
  3. 根据权利要求1所述的一种导赤丸中8种代表性成分的溶出度测定方法,其特征在于,所述步骤B中的pH=1.0盐酸溶液的制备:量取盐酸9.00mL,用水稀释至1000mL,摇匀,即得。A dissolution method for measuring 8 representative ingredients in Daochi pills according to claim 1, characterized in that the preparation of the pH=1.0 hydrochloric acid solution in step B: measure 9.00 mL of hydrochloric acid and dilute it with water to 1000mL, shake well and get it.
  4. [根据细则26改正 06.01.2023]
    根据权利要求1所述的一种导赤丸中8种代表性成分的溶出度测定方 法,其特征在于,梯度洗脱程序如下:
    流动相梯度洗脱程序
    Figure PCTCN2022138253-appb-100001
    [Amended in accordance with Rule 26 06.01.2023]
    A method for measuring the dissolution of 8 representative components in Daochi pills according to claim 1, characterized in that the gradient elution procedure is as follows:
    Mobile phase gradient elution procedure
    Figure PCTCN2022138253-appb-100001
PCT/CN2022/138253 2022-07-04 2022-12-10 Method for determining dissolution rates of eight representative components in daochi pills WO2024007532A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210779442.5 2022-07-04
CN202210779442.5A CN115290767A (en) 2022-07-04 2022-07-04 Dissolution rate determination method for 8 representative ingredients in red blood-guiding pill

Publications (1)

Publication Number Publication Date
WO2024007532A1 true WO2024007532A1 (en) 2024-01-11

Family

ID=83823197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/138253 WO2024007532A1 (en) 2022-07-04 2022-12-10 Method for determining dissolution rates of eight representative components in daochi pills

Country Status (2)

Country Link
CN (1) CN115290767A (en)
WO (1) WO2024007532A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115290767A (en) * 2022-07-04 2022-11-04 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) Dissolution rate determination method for 8 representative ingredients in red blood-guiding pill
CN115876908A (en) * 2022-07-04 2023-03-31 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) Method for simultaneously determining contents of 24 components in red-blood-guiding pill

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102139008A (en) * 2010-02-03 2011-08-03 天津中新药业集团股份有限公司隆顺榕制药厂 Quality control method of Xiaoer daochi tablet
CN114487154A (en) * 2021-12-20 2022-05-13 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) Method for detecting dissolution rate of Sijisanhuang tablets
CN115290767A (en) * 2022-07-04 2022-11-04 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) Dissolution rate determination method for 8 representative ingredients in red blood-guiding pill

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102139008A (en) * 2010-02-03 2011-08-03 天津中新药业集团股份有限公司隆顺榕制药厂 Quality control method of Xiaoer daochi tablet
CN114487154A (en) * 2021-12-20 2022-05-13 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) Method for detecting dissolution rate of Sijisanhuang tablets
CN115290767A (en) * 2022-07-04 2022-11-04 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) Dissolution rate determination method for 8 representative ingredients in red blood-guiding pill

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LI LING-YUN; WANG YUN; LIU MENG-JIAO; ZHANG XUE; LI XIAO-QING; DAI YE-JIA; MA YIN-LIAN; ZHANG CUN: "Analysis of Chemical Components in Zhizi Jinhua Wan by UPLC-Q-TOF-MS/MS", CHINESE JOURNAL OF EXPERIMENTAL TRADITIONAL MEDICAL FORMULAE, ZHONGGUO ZHONGYI KEXUEYUAN ZHONGYAO YANJIUSUO, CN, vol. 23, no. 14, 20 July 2017 (2017-07-20), CN , pages 1 - 11, XP009551700, ISSN: 1005-9903 *
LU BINAN, LIU YUETAO, YIN LIANHONG, WANG XIAONA, PENG JINYONG: "Simple and reliable methods for the determination of sixteen marker components for quality control of Daochi pill by HPLC coupled with diode array detection", PHYTOCHEMICAL ANALYSIS, J. WILEY, HOBOKEN, USA, vol. 20, no. 5, 1 September 2009 (2009-09-01), Hoboken, USA, pages 385 - 394, XP093125676, ISSN: 0958-0344, DOI: 10.1002/pca.1138 *
SHI, YONGQING; KANG, SHU-HE; WANG, AI-JUN: "Simultaneous Determination of Geniposide, Paeoniflorin, Baicalin and Berberine Hydrochloride in Daochi Pills by HPLC", CHINESE TRADITIONAL PATENT MEDICINE, GUOJIA YIYAO GUANLIJU, ZHONGCHENGYAO QINGBAO ZHONGXINZHAN, CN, vol. 35, no. 7, 20 July 2013 (2013-07-20), CN , pages 1462 - 1465, XP009552296, ISSN: 1001-1528, DOI: 10.3969/j.issn.1001-1528.2013.07.023 *
XIAO, YA ET AL.: "Determination of the dissolution rates of three ingredients in Gardenia Jinhua Pills from different manufacturers", TIANJIN PHARMACY, CHINA, vol. 29, no. 4, 28 August 2017 (2017-08-28), China , pages 22 - 33, XP009552298, ISSN: 1006-5687 *

Also Published As

Publication number Publication date
CN115290767A (en) 2022-11-04

Similar Documents

Publication Publication Date Title
WO2024007532A1 (en) Method for determining dissolution rates of eight representative components in daochi pills
CN109307721B (en) Detection method for determining content of effective components in leech capsule by HPLC-QQQ/MS method
WO2024007531A1 (en) Method for simultaneously measuring content of 24 ingredients in daochi wan
CN107703244B (en) The measuring method of 14 kinds of chemical composition contents in a kind of Chinese medicine composition
CN109324126B (en) Method for simultaneously determining 9 chemical components in spina date seeds by using UPLC-MS/MS
CN110231424B (en) Method for simultaneously and quantitatively detecting main components of Shuangshen Ping lung granules in blood plasma
CN109828062A (en) A kind of Radix Astragali builds the measuring method of 18 kinds of component contents in middle ball
CN110849983A (en) Quantitative analysis method for twelve components of astragalus mongholicus Jianzhong pills in rat plasma
CN114487154B (en) Method for detecting dissolution rate of Siji Sanhuang tablets
CN104914199A (en) Determining method for contents of twelve components in traditional Chinese medicine composition preparation
CN111272902A (en) Method for detecting drug concentration of digocalcitol in blood
CN111624295B (en) Quality detection method of 'Jihui Tongbiang' capsule
CN116183805B (en) Method for detecting and evaluating components of mulberry chrysanthemum cold granules
CN114113403B (en) Method for determining liquid chromatography-mass spectrometry (LC-MS) of Hedan tablets
CN108776183B (en) Quality control method of rhubarb and liquorice decoction
CN110988198A (en) Content determination method of bi-tong ning capsules
CN110618231A (en) Preparation process and quality standard research of Baihu decoction granules
CN116298001A (en) Vitex negundo particle and detection method and application of fingerprint thereof
CN113866306B (en) HPLC (high Performance liquid chromatography) characteristic spectrum detection method of pharmaceutical preparation
CN115840011A (en) Method for analyzing telmisartan concentration in plasma sample by using liquid chromatography-tandem mass spectrometry
CN114563497A (en) Quantitative fingerprint detection method for bupleurum tenue capsule components
CN111239319A (en) Method for measuring content of panax japonicus saponin IVa in laryngopharynx clearing oral liquid
Zheng et al. Simultaneous determination of 14 components in Shuanghua Baihe tablets by ultrasonic-assisted extraction and HPLC-MS/MS
Zhang et al. Simultaneous determination of eight active components in chloroform extracts from raw and vinegar-processed Genkwa flos using HPLC-MS and identification of the hepatotoxic ingredients with an HL-7702 cell
CN117805273B (en) Quantitative detection method and application of 5 aristolochic acid substances in diarrhea-relieving capsule

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22950089

Country of ref document: EP

Kind code of ref document: A1